retatrutide triple agonist glp-1 gip glucagon phase 2 obesity vs Survodutide: vs Dual Comparison for and MASH - Which Is Better? | PPW Retatrutide for weight loss: Study
Description
This article is accompanied by an Editorial
The GLP-1 market growth is driven by advancements in drug formulations, particularly the development of oral and long-acting therapies
doi: 10.3389/fimmu.2022.772446 27 RichardsPParkerHEAdriaenssensAEHodgsonJMCorkSCTrappSet al
Pharmaceutical companies are exploring various delivery methods, including long-acting injectables and oral formulations
[DOI] [PubMed] [Google Scholar] 433.Quoyer J., Longuet C., Broca C., Linck N., Costes S., Varin E
